免疫检查点抑制剂诱导性心肌炎的心脏MRI特征与预后价值
这项回顾性研究分析了33例免疫检查点抑制剂诱导性心肌炎(ICI-M)患者的心脏MRI特征,并与21例计划接受ICI治疗的肿瘤患者及85例病毒性心肌炎患者比较。ICI-M患者整体原生T1、ECV和T2 z评分更高,晚期钆增强(LGE)更常见且更易累及室间隔及壁中层;室间隔LGE是1年主要不良心血管事件(MACE)的唯一心脏MRI预测因子(校正后HR 2.7)。
要点
- ICI-M患者LGE发生率82%(27/33),高于计划接受ICI治疗者的10%(2/21),但低于病毒性心肌炎的100%(85/85)。
- ICI-M的LGE更常累及室间隔(48% vs 29%)和壁中层(33% vs 2%),与病毒性心肌炎不同。
- 室间隔LGE是ICI-M患者1年MACE的唯一心脏MRI预测因子(校正后HR 2.7,95%CI 1.1-6.7)。
核心结论
- ICI-M的心脏MRI特征似乎不同于计划接受ICI治疗的患者和病毒性心肌炎患者;室间隔LGE可能是ICI-M患者主要心血管事件的预测因子。
研究设计与样本
- 回顾性研究,2017年5月至2020年1月,纳入33例ICI-M患者(平均年龄68岁±14,23例男性)、21例计划接受ICI治疗的肿瘤患者(平均年龄65岁±14,14例男性)和85例病毒性心肌炎患者(平均年龄32岁±13,67例男性),比较心脏MRI表现并用Cox比例风险模型探索MACE预测价值。
关键影像表现/征象
- ICI-M患者整体原生T1 z评分高于计划接受ICI治疗组(1.79±1.93 vs 0.03±0.85,P<.001)。
- ICI-M患者ECV z评分高于计划接受ICI治疗组(2.59±1.97 vs 1.34±0.57,P=.03)。
- ICI-M患者T2 z评分高于计划接受ICI治疗组(0.88±1.96 vs -0.76±1.41,P=.002)。
- ICI-M患者LGE发生率82%(27/33)高于计划接受ICI治疗组的10%(2/21)(P<.001)。
- ICI-M患者LGE发生率82%(27/33)低于病毒性心肌炎的100%(85/85)(P<.001),但更易累及室间隔(48% vs 29%,P<.001)和壁中层(33% vs 2%,P<.001)。
诊断标准与关键数值
- ICI-M患者整体原生T1 z评分1.79±1.93,ECV z评分2.59±1.97,T2 z评分0.88±1.96。
- 计划接受ICI治疗组整体原生T1 z评分0.03±0.85,ECV z评分1.34±0.57,T2 z评分-0.76±1.41。
- 室间隔LGE预测1年MACE的校正后风险比HR 2.7(95%CI 1.1, 6.7;P=.03),校正峰值肌钙蛋白后仍显著。
临床应用与阅片要点
- 在ICI治疗患者中,心脏MRI发现室间隔LGE时,可结合峰值肌钙蛋白评估1年MACE风险。
- ICI-M的LGE表现与病毒性心肌炎不同,报告时应描述LGE的分布(室间隔、壁中层)及Mapping z评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Cardiac MRI features are not well-defined in immune checkpoint inhibitor (ICI)-induced myocarditis (ICI-M), a severe complication of ICI therapy in patients with cancer. Purpose To analyze the cardiac MRI features of ICI-M and to explore their prognostic value in major adverse cardiovascular events (MACE). Materials and Methods In this retrospective study from May 2017 to January 2020, cardiac MRI findings (including late gadolinium enhancement [LGE], T1 and T2 mapping, and extracellular volume fraction [ECV] z scores) of patients with ICI-M were compared with those of patients with cancer scheduled to receive ICI therapy (pre-ICI group) and patients with viral myocarditis. As a secondary objective, the potential value of cardiac MRI for predicting MACE in patients with ICI-M by using Cox proportional hazards models was explored. Results Thirty-three patients with ICI-M (mean age ± standard deviation, 68 years ± 14; 23 men) were compared with 21 patients scheduled to receive to ICI therapy (mean age, 65 years ± 14; 14 men) and 85 patients with viral myocarditis (mean age, 32 years ± 13; 67 men). Compared with the pre-ICI group, patients with ICI-M showed higher global native T1, ECV, and T2 z scores (0.03 ± 0.85 vs 1.79 ± 1.93 [P < .001]; 1.34 ± 0.57 vs 2.59 ± 1.97 [P = .03]; and -0.76 ± 1.41 vs 0.88 ± 1.96 [P = .002], respectively), and LGE was more frequently observed (27 of 33 patients [82%] vs two of 21 [10%]; P < .001). LGE was less frequent in patients with ICI-M than those with viral myocarditis (27 of 33 patients [82%] vs 85 of 85 [100%]; P < .001) but was more likely to involve the septal segments (16 of 33 patients [48%] vs 25 of 85 [29%]; P < .001) and midwall layer (11 of 33 patients [33%] vs two of 85 [2%]; P < .001). Septal LGE was the only cardiac MRI predictor of MACE at 1 year even after adjustment for peak troponin (adjusted hazard ratio, 2.7 [95% CI: 1.1, 6.7]; P = .03). Conclusion Cardiac MRI features of immune checkpoint inhibitor (ICI)-induced myocarditis (ICI-M) seem to differ from those in patients scheduled to receive ICIs and patients with viral myocarditis. Septal late gadolinium enhancement might be a predictor of major cardiovascular events in patients with ICI-M. Clinical trial registration no. NCT03313544 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Edelman and Pursnani in this issue.
引用
- Cadour, Cautela, Rapacchi, et al. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022. PMID: 35230185. doi:10.1148/radiol.211765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。